Challenges Related to Out-of-Pocket Costs in Heart Failure Management

Circulation Heart Failure, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 28, 2025

High out-of-pocket costs and financial toxicity related to heart failure treatment are substantial concerns. Two of 4 pillars guideline-directed medical therapy for with reduced ejection fraction, example, carry high that may attenuate their uptake. Furthermore, rarely occurs in isolation. Many patients have other comorbidities require treatment, further driving up patients’ costs. Developing plans improve mortality without subjecting can be challenging several reasons. First, accrue from multiple domains depend on a variety insurance pharmacy-related factors make determining patient-specific cost estimates complicated. Second, strategies mitigate involve health policy-level interventions patient-level interventions. These own unique sets challenges. Third, integrating into shared decision-making requires nuanced discussions about whether is worth the cost. Though has been advocated, there little data how best conduct these discussions. Health policies like Inflation Reduction Act 2022 provide relief some patients, efforts transparency potential beneficial. Over long term, policy solutions such as value-based design patient engagement emphasize enhancing important yield durable results.

Language: Английский

A Costly Cure: Understanding and Addressing Financial Toxicity in Cardiovascular Disease Health Care Within the Domain of Social Determinants of Health

Methodist DeBakey Cardiovascular Journal, Journal Year: 2024, Volume and Issue: 20(5), P. 15 - 26

Published: Jan. 1, 2024

Cardiovascular disease (CVD) represents a significant financial burden on patients and families, compounded by both direct indirect healthcare costs. The increasing prevalence of CVD, coupled with the rising costs treatment, exacerbates toxicity-defined as economic strain associated physical, emotional, behavioral consequences patients. This review explores scope toxicity in CVD care, detailing its prevalence, risk factors, complex interplay social determinants health such income, insurance status, comorbidities. Drawing from models oncology, we highlight key interventions aimed at mitigating toxicity, including patient counseling, navigation, enhanced patient-physician cost discussions. By adopting these approaches, providers can better support managing their well-being, potentially improving clinical outcomes. Future research is needed to develop standardized assessment tools for implement system-wide mitigation strategies.

Language: Английский